Results 81 to 90 of about 77,580 (287)
Psoriatic arthritis – new perspectives [PDF]
Archives of Medical Science, 2019 Psoriatic arthritis (PsA) is a seronegative arthropathy with many clinical manifestations, and it may affect nearly a half of patients with psoriasis. PsA should be diagnosed as early as possible to slow down joint damage and progression of disability.
Przemysław Krakowski +6 more
openaire +3 more sources
Advanced NanoBiomed Research, EarlyView.This review highlights how autoimmune diseases arise from intertwined immunological, genetic, and environmental factors, emphasizing gut microbiota dysbiosis as a pivotal driver. It outlines emerging nanotechnology‐based strategies—such as liposomes, hydrogels, and polymeric nanoparticles—that enhance targeted drug delivery, minimize systemic toxicity,
Md. Meraj Ansari +5 more
wiley +1 more source
BMC Musculoskeletal Disorders, 2019 Background Active foot disease persists in a high proportion of people with psoriatic arthritis despite the availability of pharmacological and non-pharmacological interventions to modify the course of the disease.
Kate Carter +3 more
doaj +1 more source
Foreword: Seminars in Research 2014 Joint Experiences in Rheumatology and Dermatology [PDF]
, 2016 ..
Costanzo, Antonio +1 more
core +1 more source
Patterns of Tumor Necrosis Factor Inhibitor (TNFi) Biosimilar Use Across United States Rheumatology Practices. [PDF]
, 2020 ObjectiveIt is unclear if biosimilars of biologics for inflammatory arthritis are realizing their promise to increase competition and improve accessibility.
Bansback, Nick +8 more
core +1 more source
Mucosal‐Associated Invariant T Cells in Rheumatic Diseases
Arthritis &Rheumatology, EarlyView.Mucosal‐associated invariant T (MAIT) cells are innate‐like T cells defined by their semi‐invariant T cell receptor and restriction by the major histocompatibility complex class I–related molecule (MR1). These cells are primarily activated by microbial‐derived metabolites presented by MR1 or by cytokines.
Manon Lesturgie‐Talarek +7 more
wiley +1 more source
CLINICAL OUTCOME MEASURES OF PSORIASIS
Reumatismo, 2011 Several tools have been introduced in clinical trials to quantify the severity and the response to a given therapeutic regimen of both psoriasis and psoriatic arthritis. Each method present specific advantages and limitations.
E. Berardesca, C. Bonifati
doaj +1 more source
Viewpoint on handling anti-TNF failure in psoriasis [PDF]
, 2013 An association among the occurrence of antidrug antibodies (ADAs), diminished trough serum drug levels (TSDLs) and non-response or loss of response has been described for several tumor necrosis factor alpha (TNF) blocking agents in a variety of diseases,
BRACKE, STEFANIE, Lambert, Jo
core +1 more source
Early Psoriatic Arthritis [PDF]
Rheumatic Disease Clinics of North America, 2015 Skin psoriasis is a major risk factor for the development of psoriatic arthritis. Recent studies have shown that delayed diagnosis is associated with long-term adverse outcomes. Screening questionnaires have revealed a potential burden of undiagnosed disease. Lifestyle factors and genetic and soluble biomarkers have come under scrutiny as risk factors.
openaire +2 more sources
Autoantibody Response Toward Chromatin in Patients With Juvenile Idiopathic Arthritis
Arthritis &Rheumatology, EarlyView.Objective Patients with juvenile idiopathic arthritis (JIA) frequently exhibit antinuclear antibodies (ANAs), but the specific antigen target recognized by them and the presence of additional autoantibody specificities in patients with JIA remains elusive.
Viola Pitkänen +13 more
wiley +1 more source